Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rameen Beroukhim, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Rameen Beroukhim and Keith Ligon.
Connection Strength

3.382
  1. Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics. 2021 08 25; 37(16):2461-2463.
    View in: PubMed
    Score: 0.247
  2. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
    View in: PubMed
    Score: 0.225
  3. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat Commun. 2019 08 19; 10(1):3731.
    View in: PubMed
    Score: 0.215
  4. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 06 03; 10(1):2400.
    View in: PubMed
    Score: 0.212
  5. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
    View in: PubMed
    Score: 0.207
  6. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996.
    View in: PubMed
    Score: 0.186
  7. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96.
    View in: PubMed
    Score: 0.159
  8. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
    View in: PubMed
    Score: 0.158
  9. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93.
    View in: PubMed
    Score: 0.139
  10. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar; 45(3):285-9.
    View in: PubMed
    Score: 0.136
  11. A Molecularly Integrated Grade for Meningioma. Neuro Oncol. 2021 Sep 11.
    View in: PubMed
    Score: 0.062
  12. Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. Neuro Oncol. 2021 May 20.
    View in: PubMed
    Score: 0.061
  13. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell. 2020 12 10; 183(6):1617-1633.e22.
    View in: PubMed
    Score: 0.059
  14. Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Mol Cell. 2020 06 18; 78(6):1207-1223.e8.
    View in: PubMed
    Score: 0.057
  15. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat Genet. 2020 02; 52(2):219-230.
    View in: PubMed
    Score: 0.056
  16. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019 12; 576(7785):112-120.
    View in: PubMed
    Score: 0.055
  17. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med. 2019 10; 8(13):5988-5994.
    View in: PubMed
    Score: 0.054
  18. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol. 2019 08 05; 21(8):968-980.
    View in: PubMed
    Score: 0.054
  19. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8.
    View in: PubMed
    Score: 0.052
  20. miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. Oncogene. 2019 04; 38(16):2923-2936.
    View in: PubMed
    Score: 0.051
  21. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335.
    View in: PubMed
    Score: 0.049
  22. Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):908-917.
    View in: PubMed
    Score: 0.046
  23. Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology. 2017 07 01; 158(7):2284-2291.
    View in: PubMed
    Score: 0.046
  24. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
    View in: PubMed
    Score: 0.046
  25. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 01; 19(1):22-30.
    View in: PubMed
    Score: 0.043
  26. MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. 2016 Jun 14; 7(24):37054-37063.
    View in: PubMed
    Score: 0.043
  27. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol. 2016 06; 128(2):293-302.
    View in: PubMed
    Score: 0.042
  28. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016 Mar; 48(3):273-82.
    View in: PubMed
    Score: 0.042
  29. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
    View in: PubMed
    Score: 0.042
  30. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagn Pathol. 2016 Jan 27; 11:13.
    View in: PubMed
    Score: 0.042
  31. Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016 Jan; 126(1):165-174.
    View in: PubMed
    Score: 0.042
  32. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.041
  33. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
    View in: PubMed
    Score: 0.041
  34. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15; 21(16):3610-8.
    View in: PubMed
    Score: 0.040
  35. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7.
    View in: PubMed
    Score: 0.039
  36. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
    View in: PubMed
    Score: 0.039
  37. Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget. 2014 Nov 15; 5(21):10596-606.
    View in: PubMed
    Score: 0.039
  38. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92.
    View in: PubMed
    Score: 0.038
  39. Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study. Epilepsy Res. 2014 Jul; 108(5):843-52.
    View in: PubMed
    Score: 0.037
  40. Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta. 2014 Apr; 1845(2):294-307.
    View in: PubMed
    Score: 0.037
  41. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013 Nov; 19(11):1518-23.
    View in: PubMed
    Score: 0.036
  42. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5.
    View in: PubMed
    Score: 0.035
  43. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron. 2012 Apr 12; 74(1):41-8.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.